AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results - Reports Full-Year Adjusted EPS of $3.32, Up 5.7 Percent; GAAP EPS $1.10- Delivers Fourth-Quarter Adjusted Revenue of $5.371 Billion, Up 8.9 Percent Over Fourth-Quarter 2013 (Up 5.1 Percent On a Reported Basis); GAAP Revenue $5.452 Billion- Revenue Growth in the Quarter Reflects 14.4 Percent Global Operational Sales Growth from HUMIRA (Up 10.6 Percent on a Reported Basis) and Strong Growth from Other Key Products- Delivers Adjusted Gross Margin Improvement of 410 Basis Points in the Fourth Quarter- Reports Fourth-Quarter Adjusted EPS of $0.89, Up 8.5 Percent; GAAP EPS ($0.51)- Launches Interferon-Free HCV Regimen Following Approval in United States, Europe and Canada- Confirms 2015 Adjusted EPS Guidance Range, Reflecting Industry-Leading Growth Versus the Prior Year

, Jan. 30, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2014. "AbbVie delivered exceptional performance in 2014 with sales and earnings well above our original projections for the year," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We returned to growth in 2014, a year ahead of schedule, and we expect to continue building on that momentum in 2015 with another year of strong performance.  For 2015, we're focused on commercial and operational execution and the advancement of our promising pipeline as we build the company for long-term sustainable growth." Fourth-Quarter...